Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
因塞特(US:INCY) Businesswire·2025-09-17 13:00WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EADV25--Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025. ...